The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07552285

Enrollment

300

Registered

2026-04-27

Start date

2025-05-01

Completion date

2027-06-01

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer, Prostate Cancer (Diagnosis)

Brief summary

The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC，OGSE,CEST,IVIM,etc.The main question it aims to answer is: Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.

Interventions

OTHERobservational study

The researchers will conduct observations, collect data and conduct follow-ups on the participants, but will not actively alter their treatment or health conditions.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

1. Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels; 2. Patients with no prior history of other tumors; 3. Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates.

Exclusion criteria

1. The patient has a history of malignant tumors and has received corresponding treatment; 2. Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc.; 3. Patients who have previously undergone radical prostatectomy for prostate cancer.

Design outcomes

Primary

Measure	Time frame
Microstructure parameters related to the OGSE sequence	Within one week after the MRI scan
CEST sequence-related numerical values	Within one week after the MRI scan
MAGIC sequence-related numerical values	Within one week after the MRI scan
IVIM sequence-related numerical values	Within one week after the MRI scan

Secondary

Measure	Time frame
Regular sequence-related numerical values	Within one week after the MRI scan

Countries

China

Contacts

CONTACTQian Zhang

zhangqian0194@163.com+86 15137562688

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026